(Q39667607)

13 September 2017

title

The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination (English)

1 reference

13 September 2017

1 reference

Newcastle disease virus

object named as

Newcastle Disease Virus

1 reference

Jing Ni

1

1 reference

13 September 2017

Volker Schirrmacher

series ordinal

2

1 reference

13 September 2017

Philippe Fournier

series ordinal

3

1 reference

13 September 2017

language of work or name

English

0 references

publication date

13 August 2010

1 reference

13 September 2017

1 reference

13 September 2017

volume

28

1 reference

13 September 2017

issue

42

1 reference

13 September 2017

page(s)

6891-6900

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

13 September 2017

1 reference

Cancer antigens: immune recognition of self and altered self

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Non-viral gene transfer: applications in developmental biology and gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Gene therapy -- promises, problems and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

DNA vaccination and gene therapy: optimization and delivery for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Strategies for effective naked-DNA vaccination against infectious diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

The perfect mix: recent progress in adjuvant research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Genetic adjuvants for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Optimization and delivery of plasmid DNA for vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

DNA vaccines and adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Modulating vaccine responses with dendritic cells and Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Frequent EpCam protein expression in human carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

How do adjuvants work? Important considerations for new generation adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Evaluation of particulate systems supporting tumor cell fractions in a preventive vaccination against intracranial rat glioma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Innate immunity: impact on the adaptive immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Polyvalent DNA vaccines with bidirectional promoters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Danger signals: SOS to the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Translating innate immunity into immunological memory: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Superiority of the ear pinna over muscle tissue as site for DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Tumor immunity and autoimmunity induced by immunization with homologous DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Coupling and uncoupling of tumor immunity and autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Type I interferon-mediated stimulation of T cells by CpG DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Type I interferons keep activated T cells alive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Identification of the anti-viral activity as interferon and characterization of the human effector lymphocyte subpopulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Links between innate and adaptive immunity via type I interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Targeting anti-tumor DNA vaccines to dendritic cells via a short CD11c promoter sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

Viral hemagglutinin augments peptide-specific cytotoxic T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.011

10.1016/J.VACCINE.2010.08.011

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference